All In Biotech

Drug Trial Radar · NCT05608044

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination With Balstilimab (AGEN2034) or Investigator's Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 234 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

234

Actual

Start

Nov 30, 2022

Primary completion

Sep 2027

Study completion Sep 2029

Sponsor

Lead sponsor
Agenus Inc.Industry
Sponsor type
Industry
First posted
Nov 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab or standard-of-care treatments in participants with refractory metastatic colorectal cancer.

Conditions

  • Metastatic Colorectal Cancer

Interventions

  • BotensilimabDrug

    An anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody.

  • BalstilimabDrug

    An anti-programmed death (ligand) 1 \[PD-(L)1\] monoclonal antibody.

  • Standard of CareDrug

    Regorafenib or trifluridine and tipiracil.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: First dose through up to 2 years

Locations

65 sites in 8 countries. Site status is shown where the registry gives one.

  • HonorHealth Research Institute

    Scottsdale, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • Keck School of Medicine of the University of Southern California

    Los Angeles, California

  • Rocky Mountain Cancer Center - Aurora

    Aurora, Colorado

  • University of Colorado

    Denver, Colorado

  • Medical Oncology Hematology Consultants

    Newark, Delaware

  • Florida Cancer Specialists and Research Institute - Lake Mary

    Lake Mary, Florida

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Atlantic Health System - Morristown Medical Center

    Morristown, New Jersey

  • Weill Cornell Medicine

    New York, New York

  • Mount Sinai Hospital - New York

    New York, New York

  • Memorial Sloan Kettering

    New York, New York

  • Cleveland Clinic

    Cleveland, Ohio

  • Earle A. Chiles Research Institute - Robert W. Franz Cancer Center - Providence Cancer Institute

    Portland, Oregon

  • Oregon Health & Science University (OHSU)

    Portland, Oregon

  • Lifespan Clinical Research Center/Cancer Institute (Providence Rhode Island)

    East Providence, Rhode Island

  • Tennessee Oncology Nashville (Sarah Cannon)

    Nashville, Tennessee

  • Vanderbilt University School of Medicine

    Nashville, Tennessee

  • Texas Oncology - Austin Midtown

    Austin, Texas

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • MDACC

    Houston, Texas

  • Virginia Cancer Specialists/NEXT Virginia

    Fairfax, Virginia

  • Swedish Cancer Institute

    Seattle, Washington

  • Northwest Cancer Center Specialists - Vancouver Cancer Center - Compass Oncology Vancouver

    Vancouver, Washington

  • Antwerp University Hospital (UZA)

    Edegem, Belgium

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

  • Hospital Sirio Libanes Brasilia

    Brasília, Brazil

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia

    Ijuí, Brazil

  • Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa

    Porto Alegre, Brazil

  • Instituto Sul Mineiro de Oncologia - ONCOMINAS

    Pouso Alegre, Brazil

  • Instituto Americas

    Rio de Janeiro, Brazil

  • Hospital A.C. Camargo Cancer Center

    São Paulo, Brazil

  • Centro Paulista de Oncologia

    São Paulo, Brazil

  • Centro de Pesquisas Clinicas da Fundação Doutor Amaral Carvalho

    Jaú, São Paulo, Brazil

  • Service d'Oncologie Medicale - CHRU Besancon

    Besançon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Hôpital Saint Antoine/AP-HP Hopital Saint Antoine (Pierre and Marie Curie University)

    Paris, France

  • CHU Poitiers - Pole Regional de Cancerologie de Poitiers (PRC)

    Poitiers, France

Showing 40 of 65 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.